申请人:Neogenesis Pharmaceuticals, Inc.
公开号:US20040038993A1
公开(公告)日:2004-02-26
The invention relates to the inhibition of hepatitis C virus (HCV) replication. In particular, embodiments of the invention provide compounds and methods for inhibiting HCV RNA-dependent RNA polymerase enzymatic activity. The invention also provides compositions and methods for the prophylaxis and treatment of HCV infection.
本发明涉及抑制丙型肝炎病毒(HCV)复制的方法。具体而言,本发明的实施例提供了抑制HCV RNA依赖性RNA聚合酶酶活性的化合物和方法。本发明还提供了用于预防和治疗HCV感染的组合物和方法。